BACKGROUND Oncocytic carcinoma of the thyroid is a rare disease,characterized by a poor prognosis and low response rate to radioiodine therapy.Crizotinib is a specific anaplastic lymphoma kinase(ALK)inhibitor,which wa...BACKGROUND Oncocytic carcinoma of the thyroid is a rare disease,characterized by a poor prognosis and low response rate to radioiodine therapy.Crizotinib is a specific anaplastic lymphoma kinase(ALK)inhibitor,which was initially developed in non-small cell lung cancer.Other solid tumors harboring a translocation in ALK have been described,such as renal carcinoma,thyroid,colorectal,ovarian cancers,and spitzoid melanoma.The research of ALK rearrangements in thyroid tumor is a promising therapeutic track,and treatments need to be explored.CASE SUMMARY We report the case of a 76-year-old woman with a history of multinodular goiter,who was hospitalized for impairment of her general condition.She was diagnosed with metastatic oncocytic thyroid cancer.Synchrone metastases were found:Multiple mediastinal lymphadenopathies,lytic bone lesions and bilateral mammary lumps.Fluorescence in situ hybridization analysis revealed an ALK rearrangement in 61%of cells.No other mutation was found.A tumor board discussion based on molecular characteristics of the tumor suggested initiating a daily treatment by crizotinib,a specific ALK inhibitor.A positron emission tomography scan performed 4 mo after the initiation of crizotinib showed a complete metabolic response.CONCLUSION This case highlights an unexpected efficacy of crizotinib in an ALK-rearranged thyroid tumor,and the need of further assessments.展开更多
Corneal ulcers,especially of fungal origin,are a relatively common clinical entity within the spectrum of keratitis in tropical countries.The persistence of a non-healing epithelial defect is a known complication of t...Corneal ulcers,especially of fungal origin,are a relatively common clinical entity within the spectrum of keratitis in tropical countries.The persistence of a non-healing epithelial defect is a known complication of these ulcers.Despite advances in medical therapy,the management of this condition is still challenging.CACICOL20^(®)is a new ophthalmic matrix therapy that has been proved efficient as a corneal healing agent.To the best of our knowledge there have been reports of the limited use of matrix therapy in ocular healing,specifically in fungal keratitis.We report 2 cases of the efficacy of it as an adjuvant to topical amphotericin B in treating non-healing epithelial defects secondary to fungal corneal ulcers.展开更多
文摘BACKGROUND Oncocytic carcinoma of the thyroid is a rare disease,characterized by a poor prognosis and low response rate to radioiodine therapy.Crizotinib is a specific anaplastic lymphoma kinase(ALK)inhibitor,which was initially developed in non-small cell lung cancer.Other solid tumors harboring a translocation in ALK have been described,such as renal carcinoma,thyroid,colorectal,ovarian cancers,and spitzoid melanoma.The research of ALK rearrangements in thyroid tumor is a promising therapeutic track,and treatments need to be explored.CASE SUMMARY We report the case of a 76-year-old woman with a history of multinodular goiter,who was hospitalized for impairment of her general condition.She was diagnosed with metastatic oncocytic thyroid cancer.Synchrone metastases were found:Multiple mediastinal lymphadenopathies,lytic bone lesions and bilateral mammary lumps.Fluorescence in situ hybridization analysis revealed an ALK rearrangement in 61%of cells.No other mutation was found.A tumor board discussion based on molecular characteristics of the tumor suggested initiating a daily treatment by crizotinib,a specific ALK inhibitor.A positron emission tomography scan performed 4 mo after the initiation of crizotinib showed a complete metabolic response.CONCLUSION This case highlights an unexpected efficacy of crizotinib in an ALK-rearranged thyroid tumor,and the need of further assessments.
基金Supported by Universiti Sains Malaysia Study Grant(Grant No.304/PPSP/6139048).
文摘Corneal ulcers,especially of fungal origin,are a relatively common clinical entity within the spectrum of keratitis in tropical countries.The persistence of a non-healing epithelial defect is a known complication of these ulcers.Despite advances in medical therapy,the management of this condition is still challenging.CACICOL20^(®)is a new ophthalmic matrix therapy that has been proved efficient as a corneal healing agent.To the best of our knowledge there have been reports of the limited use of matrix therapy in ocular healing,specifically in fungal keratitis.We report 2 cases of the efficacy of it as an adjuvant to topical amphotericin B in treating non-healing epithelial defects secondary to fungal corneal ulcers.
